Mapping and understanding exitrons in human cancer
Genome-wide mapping and characterization of exitrons in human cancer
['FUNDING_R01'] · NORTHWESTERN UNIVERSITY AT CHICAGO · NIH-10857322
This study is looking at how certain changes in RNA processing, called exitron splicing events, might affect cancer growth and treatment responses, with the hope of finding new ways to improve cancer vaccines and therapies for patients like you.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | NORTHWESTERN UNIVERSITY AT CHICAGO (nih funded) |
| Locations | 1 site (CHICAGO, UNITED STATES) |
| Trial ID | NIH-10857322 on ClinicalTrials.gov |
What this research studies
This research investigates the role of exitron splicing events in human cancers, which are variations in RNA processing that can lead to altered protein functions. By utilizing advanced sequencing technologies and computational algorithms, the study aims to identify and characterize these non-canonical splicing events that may contribute to tumor progression and resistance to therapies. The researchers will focus on how these exitron splicing events can generate unique protein isoforms and potentially create new targets for cancer vaccines and T-cell therapies. Patients may benefit from insights gained into how these splicing events affect cancer development and treatment responses.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with various types of cancer, particularly those who may benefit from novel therapeutic approaches.
Not a fit: Patients with non-cancerous conditions or those not exhibiting significant alternative splicing events may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to new cancer treatments and vaccines that target specific splicing events associated with tumor growth.
How similar studies have performed: Other research has shown promise in targeting alternative splicing events in cancer, suggesting that this approach could yield valuable insights and therapeutic options.
Where this research is happening
CHICAGO, UNITED STATES
- NORTHWESTERN UNIVERSITY AT CHICAGO — CHICAGO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: YANG, RENDONG — NORTHWESTERN UNIVERSITY AT CHICAGO
- Study coordinator: YANG, RENDONG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.